CoImmune company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

coimmune.com

Executives

13

Board of Directors

5

CoImmune Board of Directors

5 Board of directors

CoImmune has 5 board of directors, including Brian Underdown.

Name

Firm

Work History

Other Seats

Brian Underdown

Brian Underdown joined Lumira Capital (formerly, MDS Capital Corp) in 1997. His focus has been on new company formation in both Canada and the United States. Prior to joining MDSCC, Dr. Underdown held a number of senior management positions in the biopharmaceutical industry and in universities. Dr. Underdown obtained his Ph.D. in immunology from McGill University and undertook post-doctoral studies at Washington University School of Medicine. During his academic career, he focused on immune-mediated diseases as well as vaccine development. During his tenure at MDSCC, Dr. Underdown has focused on new investment opportunities and building value as a board member in a number of companies including, ID Biomedical, Trillium Therapeutics and Cytochroma Inc. He has been actively involved in policy development and grant administration with a number of government and non-governmental organizations that support research, especially as it applies to commercial development.

CoImmune

Hubert Birner

CoImmune

Hubert Birner

CoImmune

Phil Tracy

Phil Tracy joined Intersouth in 1997. His pharmaceutical background provides Intersouth with extensive experience in the healthcare industry. He serves on the boards of directors of two Intersouth portfolio companies and has served as interim CEO of an Intersouth portfolio company.Address: 406 Blackwell Street,Suite 200,Durham, NC 27701,919.493.6640,The majority of Phil's career was spent at Burroughs Wellcome Co., a major research-based pharmaceutical company with $1.2 billion in sales and 5,000 employees. At Burroughs Wellcome, he served as President and CEO from 1989 until the company's merger with Glaxo in 1995.Address: 406 Blackwell Street,Suite 200,Durham, NC 27701,919.493.6640,Phil has served on the boards of directors of the Pharmaceutical Research and Manufacturers Association of America and the Nonprescription Drug Manufacturers Association. He has also served as chairman of the board of visitors for the Duke University Medical Center and as a member of the board of visitors for the University of North Carolina at Chapel Hill.Address: 406 Blackwell Street,Suite 200,Durham, NC 27701,919.493.6640,Phil currently serves on the boards of directors of the Burroughs Wellcome Fund and Peace College. He received a B.A. from the University of Nebraska and a J.D. and L.L.B. from George Washington University.Address: 406 Blackwell Street,Suite 200,Durham, NC 27701,919.493.6640

CoImmune

Sander van Deventer

Sander has extensive experience in translational research with particular emphasis on drug development, and significant regulatory experience with the European Agency for the Evaluation of Medicinal Products (EMEA) and Food and Drug Administration (FDA.) He is both partner with Forbion Capital Partners, and professor of translational gastroenterology at Leiden University Medical Center. Sander was part of the original ABN AMRO Capital Life Sciences (AAC LS) team, before it became the independent body Forbion. He joined as venture partner at AAC LS in 2004. Sander has significant experience in the medical and life sciences field. As such, he has been a consultant to all major pharma and to a significant number of large biotech companies. He is co-founder of the gene therapy company Amsterdam Molecular Therapeutics, and currently holds a part-time position on the company's board as Chief Scientific Officer. Sander also holds a board seats at Argos Therapeutics in Durham, NC, USA. Sander has also held positions on the advisory boards of the FDA and the EMEA. He has advised the Dutch government on several projects, including the national colorectal screening program and the translational gene therapy program. Sander is the author of more than 80 book chapters and 350 peer reviewed scientific papers. He has organized several large international scientific conferences, and under his supervision more than 30 students have completed their PhD thesis. In 1995, Sander became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam, where he worked on therapeutic signal transduction inhibition, gene therapy, and (genetically engineered) probiotics. His scientific involvement included the organization of the genomics and proteomics initiative at the University of Amsterdam. In addition, Sander was Chairman of the Anton Meelmeijer Center for Genomics and Proteomics. From 2001 until 2004, he was chairman of the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam. Sander was trained and board certified in internal medicine and gastroenterology, and received his medical degree and doctor of philosophy from the University of Amsterdam. His thesis was based on the biological activities of bacterial lipopolysaccharides in humans. Following graduation, Sander worked as a scientist in the Laboratory for Medical Biochemistry, Rockefeller University, New York. It was here that TNF was discovered as a proinflammatory cytokine and Sander used this knowledge to first administer an anti-TNF monoclonal antibody (later registered as Remicade®) to patients with Crohn's disease. This was followed by other immunomodulatory interventions, targeting cytokines, cytokine receptors, T cells and signal transduction pathways, using small molecules, antibodies, peptides, proteins and antisense DNA technologies. Here he carried out preclinical development as well as the design and conduct of clinical studies.

CoImmune

Name

Brian Underdown

Hubert Birner

Hubert Birner

Phil Tracy

Sander van Deventer

Firm

Work History

Brian Underdown joined Lumira Capital (formerly, MDS Capital Corp) in 1997. His focus has been on new company formation in both Canada and the United States. Prior to joining MDSCC, Dr. Underdown held a number of senior management positions in the biopharmaceutical industry and in universities. Dr. Underdown obtained his Ph.D. in immunology from McGill University and undertook post-doctoral studies at Washington University School of Medicine. During his academic career, he focused on immune-mediated diseases as well as vaccine development. During his tenure at MDSCC, Dr. Underdown has focused on new investment opportunities and building value as a board member in a number of companies including, ID Biomedical, Trillium Therapeutics and Cytochroma Inc. He has been actively involved in policy development and grant administration with a number of government and non-governmental organizations that support research, especially as it applies to commercial development.

Phil Tracy joined Intersouth in 1997. His pharmaceutical background provides Intersouth with extensive experience in the healthcare industry. He serves on the boards of directors of two Intersouth portfolio companies and has served as interim CEO of an Intersouth portfolio company.Address: 406 Blackwell Street,Suite 200,Durham, NC 27701,919.493.6640,The majority of Phil's career was spent at Burroughs Wellcome Co., a major research-based pharmaceutical company with $1.2 billion in sales and 5,000 employees. At Burroughs Wellcome, he served as President and CEO from 1989 until the company's merger with Glaxo in 1995.Address: 406 Blackwell Street,Suite 200,Durham, NC 27701,919.493.6640,Phil has served on the boards of directors of the Pharmaceutical Research and Manufacturers Association of America and the Nonprescription Drug Manufacturers Association. He has also served as chairman of the board of visitors for the Duke University Medical Center and as a member of the board of visitors for the University of North Carolina at Chapel Hill.Address: 406 Blackwell Street,Suite 200,Durham, NC 27701,919.493.6640,Phil currently serves on the boards of directors of the Burroughs Wellcome Fund and Peace College. He received a B.A. from the University of Nebraska and a J.D. and L.L.B. from George Washington University.Address: 406 Blackwell Street,Suite 200,Durham, NC 27701,919.493.6640

Sander has extensive experience in translational research with particular emphasis on drug development, and significant regulatory experience with the European Agency for the Evaluation of Medicinal Products (EMEA) and Food and Drug Administration (FDA.) He is both partner with Forbion Capital Partners, and professor of translational gastroenterology at Leiden University Medical Center. Sander was part of the original ABN AMRO Capital Life Sciences (AAC LS) team, before it became the independent body Forbion. He joined as venture partner at AAC LS in 2004. Sander has significant experience in the medical and life sciences field. As such, he has been a consultant to all major pharma and to a significant number of large biotech companies. He is co-founder of the gene therapy company Amsterdam Molecular Therapeutics, and currently holds a part-time position on the company's board as Chief Scientific Officer. Sander also holds a board seats at Argos Therapeutics in Durham, NC, USA. Sander has also held positions on the advisory boards of the FDA and the EMEA. He has advised the Dutch government on several projects, including the national colorectal screening program and the translational gene therapy program. Sander is the author of more than 80 book chapters and 350 peer reviewed scientific papers. He has organized several large international scientific conferences, and under his supervision more than 30 students have completed their PhD thesis. In 1995, Sander became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam, where he worked on therapeutic signal transduction inhibition, gene therapy, and (genetically engineered) probiotics. His scientific involvement included the organization of the genomics and proteomics initiative at the University of Amsterdam. In addition, Sander was Chairman of the Anton Meelmeijer Center for Genomics and Proteomics. From 2001 until 2004, he was chairman of the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam. Sander was trained and board certified in internal medicine and gastroenterology, and received his medical degree and doctor of philosophy from the University of Amsterdam. His thesis was based on the biological activities of bacterial lipopolysaccharides in humans. Following graduation, Sander worked as a scientist in the Laboratory for Medical Biochemistry, Rockefeller University, New York. It was here that TNF was discovered as a proinflammatory cytokine and Sander used this knowledge to first administer an anti-TNF monoclonal antibody (later registered as Remicade®) to patients with Crohn's disease. This was followed by other immunomodulatory interventions, targeting cytokines, cytokine receptors, T cells and signal transduction pathways, using small molecules, antibodies, peptides, proteins and antisense DNA technologies. Here he carried out preclinical development as well as the design and conduct of clinical studies.

Other Seats

CoImmune

CoImmune

CoImmune

CoImmune

CoImmune

CoImmune Management Team

13 Team Members

CoImmune has 13 executives. CoImmune's current President is Jeffrey D Abbey.

Name

Work History

Title

Status

Jeffrey D Abbey

President

Current

Charles A Nicolette

Chief Executive Officer

Current

Lori R Harrelson

Chief Financial Officer

Current

Irina Tcherepanova

Chief Operating Officer

Current

Sukwoo Jeff Oh

Executive Vice President

Current

Name

Jeffrey D Abbey

Charles A Nicolette

Lori R Harrelson

Irina Tcherepanova

Sukwoo Jeff Oh

Work History

Title

President

Chief Executive Officer

Chief Financial Officer

Chief Operating Officer

Executive Vice President

Status

Current

Current

Current

Current

Current

You May Also Like

T
Traversa Therapeutics

Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

I
ImmuRx

ImmuRx is focused on cancer and chronic infectious disease by stimulating both the innate and adaptive halves of the immune system. Per the company, ImmuRx has demonstrated significantly greater immune responses and greater therapeutic benefit than most competing adjuvants in a wide variety of disease indications.

I
Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

J
JadoLabs

JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.